HCPCS Code J7326: Gel-One billing, fee schedule, and Medicare coverage

Key Takeaways

HCPCS Code J7326 describes Hyaluronan or derivative, Gel-One, for intra-articular injection, 1 mg per vial (single-injection treatment).

Medicare Part B covers J7326 under LCD L30149 at ASP+6% reimbursement, subject to failed conservative therapy documentation and diagnosis requirements.

Missing NDC on the claim, incorrect ICD-10 linkage, and absent prior authorization are the three most common denial drivers for J7326 claims.

Pabau’s claims management software can be pre-configured for Gel-One billing workflows, linking J7326, the correct ICD-10 code, and NDC to reduce denial risk.

HCPCS Code J7326: definition and official description

Most viscosupplementation denials come down to one detail that billers get wrong before the claim even leaves the practice: the wrong J-code for the wrong product. HCPCS Code J7326 is product-specific to Gel-One, Zimmer Biomet’s single-injection cross-linked hyaluronate viscosupplement. Using a sibling code like J7325 (Synvisc-One) for a Gel-One administration is an automatic denial, because payers map the code to the manufacturer’s NDC. Get the code right, and the claim has a clean path through adjudication. Get it wrong, and no amount of documentation fixes it.

The official CMS HCPCS Level II descriptor for J7326 reads: Hyaluronan or derivative, Gel-One, for intra-articular injection, 1 mg. Billing unit is 1 mg. Because Gel-One is dispensed as a single 3 mL vial containing 30 mg of cross-linked sodium hyaluronate, practices bill 30 units of J7326 per injection encounter. Pabau’s claims management software allows practices to pre-configure the unit count, NDC, and ICD-10 code for Gel-One as a saved billing template, so each encounter generates an accurate claim without manual re-entry.

When to use HCPCS Code J7326: indications and ICD-10 diagnosis codes

J7326 applies when a clinician administers Gel-One as viscosupplementation therapy for knee osteoarthritis. The injection targets the synovial joint to supplement natural hyaluronic acid lost through degenerative joint disease. Conservative therapy failure is the gatekeeper: payers require documented evidence that the patient has already tried and not adequately responded to physical therapy, analgesics, or corticosteroid injections before J7326 will be covered. Solid patient compliance documentation through each stage of conservative treatment is what makes this evidence audit-proof.

ICD-10 diagnosis codes used with J7326

The diagnosis code paired with J7326 must specifically identify the affected knee and the osteoarthritis subtype. Laterality matters: M17.11 (right primary osteoarthritis) and M17.12 (left primary osteoarthritis) are the most common pairings. Using a non-specific code like M17.9 may trigger a medical necessity review or denial depending on the MAC jurisdiction. Cross-check the current LCD L30149 companion billing and coding guidelines for the complete accepted ICD-10 list before submission, as CMS periodically updates the covered diagnosis list.

Medicare and payer coverage for J7326

Medicare Part B covers Gel-One under the viscosupplementation benefit, but coverage is not uniform across the country. Each Medicare Administrative Contractor (MAC) may have its own coverage policy, and the applicable LCD governs which patients and diagnoses qualify. Practices billing to a physical therapy or orthopedic practice through a different MAC jurisdiction than their state default should verify the active LCD before billing J7326 for the first time.

Local coverage determination (LCD) and medical necessity

LCD L30149 is the primary CMS coverage article governing intraarticular hyaluronan injections. It sets the medical necessity bar that claims must clear to be paid. Key criteria include:

• Confirmed diagnosis of knee osteoarthritis documented in the medical record
• Evidence of failed conservative therapy (typically physical therapy and/or analgesics for at least 3 months, though exact duration requirements vary by MAC policy)
• Physician attestation that the patient is not a surgical candidate or has declined surgery
• No prior viscosupplementation injection in the same knee within the covered benefit period
• Documentation of injection technique and site (intra-articular, knee joint)

Commercial payers follow varying standards. Some align closely with the Medicare LCD; others require additional radiographic evidence of joint space narrowing or impose stricter prior authorization rules. Always verify the individual payer’s medical policy for viscosupplementation before the injection date, not after.

J7326 fee schedule and Medicare reimbursement rates

Medicare reimburses J7326 under the Part B drug reimbursement methodology: ASP (Average Sales Price) plus 6%. The ASP base is recalculated quarterly by CMS and changes each January, April, July, and October. Because specific dollar figures shift every quarter, practices should check the current rate directly through the CMS Physician Fee Schedule lookup tool rather than relying on published snapshots that may be out of date.

The ASP+6% add-on covers the practice’s cost of acquiring the drug plus a handling margin. It does not cover the administration fee. The intraarticular injection administration is billed separately using the appropriate injection CPT code (typically 20610 for large joint injection), which carries its own RVU-based reimbursement. Forgetting to bill the administration code separately is a common revenue leakage point.

ASP pricing and the buy-and-bill model

Gel-One uses the buy-and-bill model for office administration. The workflow has three stages:

1. Purchase: The practice buys Gel-One directly from Zimmer Biomet or an authorized distributor. Acquisition cost relative to ASP determines the practice’s margin on each claim.
2. Administer: The clinician performs the intra-articular knee injection in the office setting. The NDC from the specific vial lot used must be recorded in the patient’s chart at time of service.
3. Bill: Submit J7326 (30 units for one 30 mg vial) with the NDC, the administering clinician’s NPI, and the paired ICD-10 code. Bill 20610 separately for the injection procedure. Good EHR integration between clinical documentation and billing reduces the manual steps in this handoff.

MAC jurisdiction also affects the allowable rate. Practices in high-cost areas may receive slightly higher reimbursements than the national average. Using AAPC’s HCPCS code lookup or the PGM Billing HCPCS tool alongside the CMS quarterly ASP file gives practices the most accurate current rate for their locality.

Prior authorization for J7326 is payer-dependent. Medicare Fee-for-Service does not require prior authorization for viscosupplementation in most MAC jurisdictions, but Medicare Advantage plans frequently do. Commercial payers vary widely: some require PA for every injection course, others only for repeat courses within a benefit year. Tracking authorization status in secure patient data systems tied to the clinical record prevents the most common denial scenario: claim submission after a PA has expired or before one has been obtained.

When PA is required, the supporting documentation package typically needs to include:

• Diagnosis confirmation (ICD-10 code and clinical description)
• Imaging report confirming osteoarthritis (X-ray showing joint space narrowing is the standard)
• Chart notes documenting conservative therapy attempts and duration
• Prescribing physician’s attestation of medical necessity
• The product name (Gel-One) and the HCPCS code (J7326) to confirm product-specific approval

Pabau’s automated billing workflows include a prior authorization tracking module that attaches PA approval records directly to the patient encounter. This keeps authorization status visible during claim generation rather than requiring staff to check a separate system before submission.

Simplify injectable drug billing with Pabau

Pabau pre-configures J-code billing workflows for buy-and-bill injectables, linking the HCPCS code, NDC, ICD-10 pairing, and prior authorization status to each encounter so your team submits clean claims the first time.

Book a demo

Documentation requirements for billing J7326

Documentation errors are responsible for a significant share of J7326 post-payment recoupments. LCD L30149 requires specific evidence in the medical record, and a payer audit will look for every item on this checklist. Incomplete records do not just cause denials on the current claim; they can trigger retrospective reviews of previous claims for the same patient.

Required documentation at a minimum:

• Diagnosis of knee osteoarthritis with ICD-10 code and supporting clinical evidence
• Documentation of failed conservative therapy (type, duration, patient response)
• Injection administration note including date, site (right vs. left knee), technique, and administering clinician
• NDC of the specific Gel-One lot administered (recorded at time of service, not retroactively)
• Informed consent
• Prior authorization reference number (when applicable)

Using digital intake forms and structured clinical note templates reduces the risk of missing a documentation field under audit pressure. Pabau’s procedure note templates can be configured to prompt clinicians for laterality, failed conservative therapy details, and injection site documentation at each encounter, satisfying the LCD L30149 compliance requirements before the note is signed. Proper documentation also supports HIPAA compliance for medical offices when records are requested during audits.

Modifiers used with J7326

Modifier selection on J7326 claims is an area competitors’ reference pages often handle superficially. The table below covers the modifiers most relevant to Gel-One billing:

RT and LT modifiers are required when billing laterality matters for payer adjudication. JW and JZ were made mandatory for Part B drug claims to improve wastage reporting accuracy. Omitting JZ when no wastage occurred is now a claim edit failure on most MACs. Use CrossCoder’s procedure-to-diagnosis crosswalk tool to verify current modifier requirements for your MAC before submitting.

Related hyaluronan HCPCS codes: how J7326 compares

J7326 sits within a family of hyaluronan J-codes (J7321 through J7325), each tied to a specific product and injection series. The most common billing error in this category is using the single-injection code for a multi-injection product or vice versa. The table below clarifies the key differences to prevent product-code mismatch denials.

Practices administering multiple viscosupplement products should use practice management software that maps each product’s NDC to its specific HCPCS code. Without that mapping, a staff member selecting the wrong code at charge entry creates a denial that takes significantly more time to fix than it took to prevent. Review the full hyaluronan J-code family via the CMS list of HCPCS codes to confirm current code-product assignments.

Common billing errors and denial reasons for J7326

Gel-One claims have a narrow margin for error. Each item below represents a pattern that triggers denials or post-payment audits in orthopedic and rheumatology practices using viscosupplementation billing.

• Missing or incorrect NDC: CMS requires the NDC on all Part B drug claims. Submitting J7326 without the NDC produces an automatic edit failure on most MACs. The NDC must match the specific Gel-One lot used, not a generic placeholder.
• Wrong ICD-10 linkage: Using a non-specific osteoarthritis code (M17.9) or an unrelated diagnosis fails medical necessity edits. The ICD-10 must be laterality-specific and match the injection site.
• Missing prior authorization: Submitting to a payer that requires PA without the approval number results in a CO-15 or CO-197 denial. The PA number must appear on the claim before submission.
• Incorrect unit count: Billing 1 unit instead of 30 units for a full 30 mg vial leaves significant reimbursement on the table. Billing more than 30 units without documentation of additional drug is fraudulent.
• Same-knee repeat injection within the covered period: Most MACs and commercial payers restrict viscosupplementation to once per benefit period per knee. Billing a second J7326 for the same knee within that window will deny on frequency edits.
• Omitting JZ modifier: Since CMS made JW/JZ reporting mandatory, submitting J7326 without either modifier triggers claim edits. When the full vial is used with no wastage, JZ is required.

Configuring prescription management software that records NDC at the point of drug administration, and using structured billing workflows tied to clinical documentation, prevents the majority of these failure modes before claims leave the practice.

HCPCS Code J7326 billing hinges on three things getting right simultaneously: the correct product-code match, complete LCD-compliant documentation, and a clean claim with the NDC and modifiers attached before submission. Any one of those failing creates a denial that costs more to fix than it would have cost to prevent.

Pabau’s claims management software lets orthopedic and rheumatology practices pre-configure Gel-One billing templates with the J7326 code, unit count, NDC crosswalk, ICD-10 pairing, and prior authorization tracking built in. Every encounter generates a claim ready for submission without manual reconstruction. To see how that works in practice, book a demo with the Pabau team.

Continue your research

Need structured templates for injection procedure documentation? Pabau’s digital forms lets practices build procedure-specific note templates that prompt clinicians for laterality, conservative therapy history, and NDC recording at every encounter.

Managing billing compliance across a multi-provider practice? Medical forms for healthcare practices covers how structured digital documentation reduces audit exposure and claim denial rates.

Want to understand how automated workflows reduce J-code billing errors? Patient care management best practices explains how integrating clinical and billing workflows cuts manual entry errors across injectable drug claims.

Frequently Asked Questions